Compare SGHC & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGHC | BIO |
|---|---|---|
| Founded | 2020 | 1952 |
| Country | Guernsey | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 8.0B |
| IPO Year | 2021 | 1994 |
| Metric | SGHC | BIO |
|---|---|---|
| Price | $12.68 | $375.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $17.33 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 2.3M | 250.5K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | N/A | ★ 142.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,583,200,000.00 |
| Revenue This Year | $16.09 | $2.74 |
| Revenue Next Year | $9.73 | $3.20 |
| P/E Ratio | $20.80 | ★ N/A |
| Revenue Growth | N/A | ★ 0.65 |
| 52 Week Low | $8.46 | $236.73 |
| 52 Week High | $15.86 | $396.23 |
| Indicator | SGHC | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 33.95 | 55.18 |
| Support Level | $12.46 | $284.88 |
| Resistance Level | $13.02 | $396.23 |
| Average True Range (ATR) | 0.41 | 9.71 |
| MACD | -0.11 | -2.69 |
| Stochastic Oscillator | 10.95 | 38.92 |
Super Group (SGHC) Ltd is a holding company that operates online sports betting and gaming businesses. The company's four operating segments-Betway, Spin, Jumpman and DGC. A majority of its revenue is generated from the Betway segment, which is a single-brand online sports betting and casino offering with licenses to operate throughout Europe, the Americas, and Africa. Spin is the company's multi-brand online casino offering, having a diverse portfolio of casino brands such as Jackpot City, Spin Casino, Dream Bingo, Mirror Bingo, etc., designed to be culturally relevant globally while aiming to offer a wide range of casino products. Geographically, the company generates maximum revenue from Africa and Middle East, followed by North America, Europe, Asia-Pacific, and South/Latin America.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.